Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...